MACROGENICS INC (MGNX) research
MACROGENICS INC- Sector
- Biotechnology
- Last price
- $4.12
- As of
MACROGENICS INC (MGNX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-14.
As of . Source: SEC EDGAR filings for MGNX. Method and limitations.
Share the MGNX intelligence card
See MGNX live in the terminal
Track MGNX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live MGNX terminal, freeActive signals for MGNX
- highCONSENSUS_SELL
3 tracked funds reduced MGNX this 2026Q2, institutional consensus
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 102.7%, EPS $-0.26 vs $-0.1283 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 97% of MGNX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of MGNX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 97% of MGNX (2026Q2)
FREE, NO ACCOUNT
Every signal on MGNX, as it fires
You are seeing 5 of 12 signals recorded on MGNX since 2026-06-03.
The five above landed across 3 days. The other 7 were recorded on 3 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MGNX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 556099109 · 2026Q2 | $12.2M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 556099109 · 2026Q2 | $11.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 556099109 · 2026Q2 | $11M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 556099109 · 2026Q2 | $4.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 556099109 · 2026Q2 | $831K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MGNX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MGNX against its peers
MGNX's operating margin of -48.7% ranks in the 81st percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | MGNX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 150M USD | 7.1M USD | 97 | 17 |
| Operating margin | -48.7% | -621.1% | 81 | 17 |
| Net margin | -49.9% | -565.5% | 81 | 17 |
| Return on equity | -134.2% | -63.4% | 33 | 19 |
Peers (23): PRQR, CAMP, ACIU, LCTX, TRDA, PYXS, BCYC, LYEL, NWBO, ANIK, PALI, GLSI, FHTX, RNAC, CYDY, IMRX, NAGE, ALXO, UPB, ZNTL, WHWK, CGEN, FATE. Left out: CUVL (no annual filing), VCRE (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (MGNX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MGNX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MGNXand get the insider, 13F, options, and confluence read in one view.